Clinical Research Directory
Browse clinical research sites, groups, and studies.
Effect of Genetic Polymorphism on the Clinical Outcome to SGLT2 Inhibitors in Heart Failure Patients
Sponsor: Ain Shams University
Summary
Heart failure with reduced ejection fraction (HFrEF) is a significant cause of morbidity and mortality. Sodium-glucose co-transporter-2 (SGLT2) inhibitors have demonstrated efficacy in improving renal outcomes in patients with HFrEF. Pharmacogenetics, the study of how genetic variations influence drug response, could elucidate inter-individual variability in treatment outcomes. This study aims to assess the impact of specific genetic variants on renal outcomes in HFrEF patients treated with SGLT2 inhibitors.
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
OBSERVATIONAL
Enrollment
200
Start Date
2023-11-22
Completion Date
2025-07-01
Last Updated
2025-03-30
Healthy Volunteers
No
Interventions
SGLT2 inhibitor (Dapagliflozin 10mg)
Renal response after 6 months of Dapagliflozin therapy among patients with heart failure reduced ejection fraction.
Locations (1)
National Heart Institute
Cairo, Egypt